domingo, 1 de diciembre de 2019

Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Dis... - PubMed - NCBI

2019 Oct 30. pii: S1525-7304(19)30286-4. doi: 10.1016/j.cllc.2019.10.012. [Epub ahead of print]

Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities.

Begnaud A1, Yang P2, Robichaux C3, Rubin N4, Kratzke R1, Melzer A5, Aliferis C1, Jacobson P6.

Author information

1: Department of Medicine, University of Minnesota, Minneapolis, MN.
2: Departments of Internal Medicine and Medical Genetics, Mayo Clinic, Scottsdale, AZ.
3: Department of Medicine, University of Minnesota, Minneapolis, MN. Electronic address: robic020@umn.edu.
4: Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
5: Section of Pulmonary and Critical Care, Minneapolis VA Healthcare System, Minneapolis, MN.
6: Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN.

Abstract

BACKGROUND:

American Indians and Alaska Natives (AI/AN) continue to experience extreme lung cancer health disparities. The state of Minnesota is home to over 70,000 AI/AN, and this population has a 2-fold increase in lung cancer mortality compared to other races within Minnesota. Genetic mutation testing in lung cancer is now a standard of high-quality lung cancer care, and EGFR mutation testing has been recommended for all adenocarcinoma lung cases, regardless of smoking status. However, genetic testing is a controversial topic for some AI/AN.

PATIENTS AND METHODS:

We performed a multisite retrospective chart review funded by the Minnesota Precision Medicine Grand Challenge as a demonstration project to examine lung cancer health disparities in AI/AN. We sought to measure epidemiology of lung cancer among AI receiving diagnosis or treatment in Minnesota cancer referral centers as well as rate of EGFR testing. The primary outcome was the rate of EGFR mutational analysis testing among cases and controls with nonsquamous, non-small-cell lung cancer. We secured collaborations with 5 health care systems covering a diverse geographic and demographic population.

RESULTS:

We identified 200 cases and 164 matched controls from these sites. Controls were matched on histology, smoking status, sex, and age. In both groups, about one third of subjects with adenocarcinoma received genetic mutation testing.

CONCLUSION:

There was no significant difference in mutation testing in AI compared to non-AI controls at large health care systems in Minnesota. These data indicate that other factors are likely contributing to the higher mortality in this group.